[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538535":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":56,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":10,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":10,"enrollmentInfo":73,"targetDuration":76,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":10,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"University of Texas Southwestern Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"POTS (Postural Orthostatic Tachycardia Syndrome)",null,"Patients meeting clinical criteria for postural orthostatic tachycardia syndrome who meet other criteria for inclusion.",[13],"Diagnostic Test: multimodal diagnostic testing",{"label":15,"type":10,"description":16,"interventionNames":17},"Healthy matched controls","Age and sex matched controls",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","multimodal diagnostic testing","Serological testing, cardiac MRI, skin biopsy, cardiovascular testing, blood volume measurements",[15,9],[25],{"name":26,"affiliation":5,"role":27},"Steven Vernino, MD PhD","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Steve Hopkins","CONTACT","214-648-9275","steve.hopkins@utsouthwestern.edu",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"UT Southwestern Medical Center","RECRUITING","Dallas","Texas","75208","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-96.80667,32.78306,{"lat":47,"lon":46},[50,52,54],{"name":51,"role":31,"phone":32,"phoneExt":10,"email":33},"Steven Hopkins",{"name":51,"role":31,"phone":53,"phoneExt":10,"email":33},"2146489275",{"name":55,"role":27,"phone":10,"phoneExt":10,"email":10},"Steven Vernino, MD, PhD",{"type":27,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Steven Vernino MD PhD","PROFESSOR",[60],{"name":61,"class":62},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100538535","phenotyping-of-postural-orthostatic-tachycardia-syndrome-pots-100538535",false,"NCT06292104","Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS)","Multimodality Deep Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS), Aim 1","Inclusion Criteria:\n\nPOTS Patients\n\n* Age ≥ 14 years, able to provide informed consent (assent with parental consent for age \\\u003C 18) and comply with procedures\n* Meets consensus criteria for POTS: (1) sustained increase in heart rate ≥ 30 bpm above supine baseline within 10 min of quiet standing or upright tilt (≥ 40 bpm in individuals 12 to 19 years of age) OR sustained upright HR (heart rate) \\>120 bpm, (2) absence of orthostatic hypotension, (3) symptoms with standing that improve with sitting or lying down, (4) resting supine heart rate \\\u003C 100 bpm, (5) orthostatic symptoms present for at least 6 months\n* Stable oral medication regimen for at least 14 days\n\nNon-POTS Control Patients\n\n* Healthy women, age 18 - 30 years, able to provide informed consent and comply with study procedures\n* Does NOT meet consensus criteria for postural tachycardia syndrome\n* No symptoms of orthostatic intolerance or dysautonomia. No history of other major medical disorder\n* Resting supine heart rate \\\u003C 100 bpm\n\nExclusion Criteria:\n\nNone of the following exclusion criteria:\n\n* Use of amphetamine-type stimulants, diuretics, selective norepinephrine reuptake inhibitor, anticholinergic medications (including tricyclic antidepressant medications), fludrocortisone, desmopressin in past 14 days\n* Use of other autonomic drugs (adrenergic agents, pyridostigmine, droxidopa, triptans, ivabradine) in past 48 hours\n* Currently receiving IVIG (Intravenous immunoglobulin), subcutaneous IgG (Immunoglobulin G), or any investigational medication (in past year)\n* Infusion of iv fluids in past 7 days\n* History or evidence of another condition explaining symptoms or orthostatic tachycardia (e.g. structural heart disease, CSF (Cerebrospinal fluid) hypovolemia, or severe traumatic brain injury)",true,"ALL","14 Years",{"count":74,"type":75},350,"ESTIMATED","1 Year","OBSERVATIONAL","This is an observational study to deeply phenotype the disorder of POTS using multiple testing modalities.",[80],"Postural Orthostatic Tachycardia Syndrome","2025-06-23",{"date":83,"type":84},"2025-06-27","ACTUAL",{"date":86,"type":84},"2024-03-05",{"date":88,"type":75},"2029-01",{"name":5,"class":6},1]